Peptide Administration Routes: Evidence, Formulation, and Safety

A peptide’s administration route cannot be evaluated from its name alone. Absorption, exposure, stability, safety, and clinical effect belong to the exact finished product: the molecular form, formulation, excipients, concentration, device, manufacturing controls, route, and administration conditions tested together.

This page explains how to assess route claims. It does not provide injection, nasal-spray, reconstitution, or self-administration instructions for unapproved research products.

Route summary

There is no defensible universal bioavailability range for “peptides by route.” Sequence, size, charge, aggregation, proteolysis, formulation, device performance, tissue physiology, and study design can all change exposure.

Route evidence belongs to the finished product

An administration claim needs more than a molecule and a route label. At minimum, determine:

1. Identity: sequence, terminal chemistry, modifications, salt form, and related substances;
2. Formulation: excipients, pH, osmolality, viscosity, preservatives, particles, and delivery matrix;
3. Quality: assay, content uniformity, stability, aggregation, sterility, and endotoxin controls where relevant;
4. Device: syringe, pen, pump, spray, tablet, patch, or other system used in the study;
5. Pharmacokinetics: intact-compound exposure, absolute bioavailability, variability, and metabolites;
6. Clinical context: population, indication, concomitant treatment, and patient-relevant outcomes; and
7. Regulatory scope: the exact approved product, label, indication, and route rather than the active ingredient in isolation.

Changing any of these can create a different product with a different evidence base. A purity result for raw material does not validate administration, and a study of one finished formulation does not validate a vial, capsule, spray, or cream made elsewhere.

Injectable routes

Intravenous administration places material directly into the vascular system, while subcutaneous and intramuscular products must leave an injection site before reaching systemic circulation. That distinction does not yield a transferable onset time or bioavailability percentage. Absorption can vary with molecular size, aggregation, excipients, concentration, local blood or lymph flow, degradation, and device performance.

Approved injectable peptides are evaluated as complete products. Their labels specify route, presentation, handling, contraindications, warnings, and administration by the intended patient or health professional. Those controls do not transfer to an unapproved lyophilized vial bearing the same peptide name.

For any product intended to be sterile, identity and chromatographic purity are only part of the quality picture. Microbial contamination, endotoxin, visible or subvisible particles, incorrect concentration, container-closure failure, and aggregation can create separate risks. CDC injection-safety guidance is written for trained health-care settings using aseptic medication preparation; it should not be converted into a do-it-yourself injection tutorial.

FDA warns that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. The agency has documented serious harm when compounded products were contaminated or contained too much or too little active ingredient.

Intranasal delivery

Intranasal delivery can support local nasal effects or systemic absorption for some purpose-built products. Direct delivery from the nose to the brain is a separate hypothesis that requires tissue or central pharmacokinetic evidence. A quick subjective effect, a plasma measurement, or activity in an animal model cannot establish the path taken in a human brain.

Nasal peptide exposure depends on factors such as molecular properties, formulation pH and osmolality, enzymatic stability, spray droplet distribution, deposition site, mucociliary clearance, nasal congestion or inflammation, swallowed fraction, and delivery-device performance. These variables help explain why results from an approved nasal product or controlled research formulation cannot validate a vendor spray.

Peptides discussed online as nasal products—including Semax, Selank, and oxytocin—must each be evaluated by exact formulation, jurisdiction, indication, and human evidence. A history of research or use in another country is not FDA approval and does not establish product equivalence.

Oral peptide delivery

Most unprotected peptides face two major barriers after swallowing: enzymatic degradation and poor passage across gastrointestinal epithelium. Successful oral peptide products therefore require molecule engineering, protective delivery systems, absorption enhancers, tightly controlled administration conditions, or some combination of these strategies.

Why oral semaglutide is not a generic example

FDA-approved oral semaglutide is co-formulated with the absorption enhancer SNAC. Human studies found that tablet erosion, food, water, and the fasting interval affected exposure. The current FDA label also describes two oral formulations with different strengths and explicitly states that they are not substitutable on a milligram-for-milligram basis.

This example demonstrates formulation specificity. It does not show that raw semaglutide, an ordinary capsule, or another peptide becomes clinically effective when swallowed. Likewise, evidence for an approved oral formulation cannot validate a compounded or “research” product merely because the ingredient name matches.

Claims that should not be grouped as oral peptides

MK-677 and 5-Amino-1MQ are small molecules, not peptides. Their oral pharmacology does not solve peptide degradation or permeability. Including them in a list of “orally bioavailable peptides” creates a category error.

Claims that BPC-157 is orally active in people also exceed the evidence. In its 2026 review, FDA reported finding no studies that administered BPC-157 to humans by the proposed oral, subcutaneous, nasal, or transdermal routes and found insufficient clinical safety information.

Buccal and sublingual delivery

The oral mucosa can avoid some gastrointestinal and hepatic barriers, but that does not make a dropper solution a validated buccal or sublingual dosage form. Salivary washout, swallowing, short residence time, enzymatic instability, epithelial permeability, formulation pH, and local tolerability all affect exposure.

Meaningful evidence should measure intact peptide in humans using the exact film, tablet, spray, gel, or other dosage form. A statement that a molecule is “small” or was placed under the tongue does not establish systemic bioavailability, clinical equivalence, or a reproducible dose.

Topical is not the same as transdermal

A topical product may act on the surface or within skin layers without producing meaningful systemic exposure. A transdermal product is designed to move an active ingredient across the skin into systemic circulation. These are different goals and require different evidence.

The stratum corneum is a substantial barrier to hydrophilic macromolecules. Palmitoylation, liposomes, nanoparticles, iontophoresis, microneedles, and other technologies can change penetration, but the delivery system becomes part of the intervention. It can also change irritation, contamination, stability, and systemic-exposure risks.

Evidence from a finished cosmetic containing GHK-Cu, Matrixyl, or acetyl hexapeptide-8 cannot establish that the raw peptide penetrates intact skin or that using a barrier-disrupting device with it is safe.

How to evaluate an administration claim

Use this sequence before treating a route statement as reliable:

1. Confirm the molecule. Is the cited material the same sequence, fragment, analog, and chemical form?
2. Confirm the formulation. Are the excipients, concentration, dosage form, and device comparable?
3. Identify the evidence level. Was exposure measured in a test tube, an animal, healthy volunteers, or the intended patient population?
4. Separate detection from delivery. Did investigators measure intact peptide, an indirect biomarker, or only a downstream effect?
5. Separate exposure from benefit. Bioavailability does not by itself prove efficacy, safety, or an appropriate indication.
6. Check variability. Look for confidence intervals, below-quantification results, food effects, device effects, and between-person spread.
7. Check the regulatory claim. Approval belongs to an exact product, route, indication, and label—not every product sharing an ingredient name.
8. Look for route-specific safety. Oral tolerance cannot establish injectable sterility; topical tolerance cannot establish nasal or systemic safety.

Research and sourcing boundaries

The peptide bioavailability guide explains pharmacokinetic terms in more depth. The peptide purity-testing guide separates identity, purity, content, sterility, and endotoxin testing. The source directory organizes public documentation and availability signals, while the sourcing policy explains why inclusion is not an endorsement for administration or human use. Use the research methodology to interpret evidence grades and the oral-peptide category to explore compounds without assuming route equivalence.

References

1. US Food and Drug Administration. Rybelsus prescribing information. 2025.
2. Bækdal TA, et al. Effect of various dosing conditions on the pharmacokinetics of oral semaglutide. Diabetes Therapy. 2021.
3. Bækdal TA, et al. Relationship between oral semaglutide tablet erosion and pharmacokinetics. Clinical Pharmacology in Drug Development. 2021.
4. Zizzari AT, et al. New perspectives in oral peptide delivery. Drug Discovery Today. 2021.
5. Illum L. Clinical opportunities provided by nasal administration of peptides. Journal of Drug Targeting. 1994.
6. Agu RU. Overview of intranasally delivered peptides: considerations for pharmaceutical development. Expert Opinion on Drug Delivery. 2019.
7. Kalluri H, Banga AK. Transdermal delivery of proteins. AAPS PharmSciTech. 2011.
8. US Food and Drug Administration. July 2026 Pharmacy Compounding Advisory Committee presentation. 2026.
9. US Food and Drug Administration. Understanding the risks of compounded drugs. Updated 2026.
10. Centers for Disease Control and Prevention. Preventing unsafe injection practices. 2024.

Bottom line

Route claims are product claims. A peptide name plus “oral,” “nasal,” “subcutaneous,” or “topical” is not enough to predict exposure, safety, or benefit. Reliable conclusions require the exact molecule, finished formulation, device, pharmacokinetic evidence, clinical context, and route-specific quality controls tested together.